Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
LabGenius expands validation of its EVA antibody-discovery platform through a…
Vedana Therapeutics Advances Migraine Antibody Pipeline | Lucid Diligence Brief
Vedana Therapeutics has emerged from stealth with $46 million in Series A…
DermaSensor AI dermatology devices | Lucid Diligence Brief
AI dermatology devices are advancing beyond validation studies as DermaSensor…
Bayer Completes Perfuse Therapeutics Acquisition for PER-001 | Lucid Diligence Brief
Bayer has closed its acquisition of Perfuse Therapeutics, securing full rights…
Merck and Protillion Biosciences Collaboration Examined | Lucid Diligence Brief
Merck and Protillion partner on AI protein design. Assess milestones, platform…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Intravacc and SynphaBase Conjugate Vaccine Partnership | Lucid Diligence Brief
Can Intravacc and SynphaBase create a streamlined synthetic glycan-to-GMP…
GNI Group Acquires Ayumi Pharmaceutical | Lucid Diligence Brief
GNI Group’s Ayumi acquisition tests Japan commercial scale, Calonal durability,…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…